why choose us

300×250 Ad Slot

Research Article: Real-World Comparison of First-Line Treatment Adherence Between Single-Agent Ibrutinib and Acalabrutinib in Patients with Chronic Lymphocytic Leukemia

Date Published: 2023-08-23

Introduction:
The need to manage multiple chronic conditions is common in older populations, as more than % of Americans over the age of have two or more chronic conditions. Therefore, polypharmacy (ie, simultaneous treatment with multiple medications) is an important consideration in this population, and consequences of such a phenomenon include increased health-care costs, adverse drug events, increased potential for drug interactions, and treatment nonadherence. Simplifying dosing regimens and the frequency of uptake can…

Read more

300×250 Ad Slot